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Summary
Primary immunodeficiency (PI) diseases are a group of primarily single-gene disorders of the immune system. Approximately
100 separate PI diseases have been described, but <20 probably account for >90% of cases. Although diverse, PI diseases share the
common feature of susceptibility to infection and result in substantial morbidity and shortened life spans. Most important,
prompt diagnosis and treatment can now lead to life-saving treatment and result in marked improvements in the quality and
length of life for persons with PI diseases.
In November 2001, a workshop was convened by CDC in Atlanta, Georgia, to discuss ways to improve health outcomes among
persons with PI disease. A multidisciplinary panel of persons knowledgeable in PI diseases and public health met to identify and
discuss public health strategies that can be applied to PI diseases and possibly for other genetic disorders. A systematic assessment
based on the established public health framework was applied to the growing group of PI diseases, whose diverse genetic mutations
span multiple components of the immune system but all lead to increased incidence and severity of infections.
During the meeting, specialists in clinical immunology, public health, genetics, pediatrics, health communication, and ethics
from state and federal agencies, academic centers, professional organizations, and advocacy foundations discussed the four compo-
nents of the public health framework as they relate to PI diseases. These four components include 1) public health assessment
(application of traditional public health methods to assess the occurrence and impact of PI diseases on communities); 2) population-
based interventions (development, implementation, and evaluation of screening tests administered to newborns and clinical
algorithms for early recognition of symptomatic persons to facilitate the earliest possible diagnosis and treatment for PI diseases);
3) evaluation of screening and diagnostic tools (to ensure their quality and appropriateness for identification of patients with PI
diseases); and 4) communication (communication with and information dissemination to health-care providers and the public to
facilitate prompt and appropriate diagnosis and intervention). The working group’s deliberations focused on challenges and
opportunities, priority research questions, and recommendations for future action for these four components. These recommenda-
tions, developed by workshop participants, will be useful to medical and public health professionals who are evaluating methods
to increase recognition of PI diseases and other genetic disorders.
Introduction
Advances in human genetics and the evolution of the
Human Genome Project will play a central role in the prac-
tice of medicine and public health in the 21st century. How-
ever, gene discovery is only the beginning. For the majority of
diseases, a gap exists between discovering or sequencing genes
and using human genomic information to improve health
outcomes (1). Public health research and policy have a crucial
role in closing that gap. Moving from gene discovery to clini-
cal and public health application requires full engagement of
public health to 1) quantify the effect of genetic discoveries
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on population health, 2) develop policies regarding and guide-
lines for the appropriate use of genetic tests and services,
3) develop interventions to improve health outcomes, 4) ini-
tiate and maintain behavior change among patients and health-
care providers, and 5) address the quality of and access to
services. Genomic breakthroughs have been identified as
major challenges for public health in the 21st century (2).
However, the usefulness of these breakthroughs in clinical
practice depends on the availability of population-based data
to determine the prevalence of gene variants among different
populations, the population-based risk for disease associated
with gene variants, gene-environment interactions, and the
effectiveness of genetic tests and services (3–5).
As part of efforts to highlight the emerging role of human
genomics in the practice of public health in the United States,
CDC, in collaboration with research, academic, clinical, and
foundation partners, evaluated public health strategies that
can be used to close the gap between gene discoveries and
clinical practice for primary immunodeficiency (PI) diseases
— approximately 100 primarily single-gene disorders of the
immune system. Identification of the genes responsible for
these conditions is progressing rapidly; therefore, a population-
based framework is needed that can be applied also to other
genetic disorders and gene discoveries. This report describes the
concerns, challenges, and opportunities and provides
recommendations for public health action regarding such a
framework.
Background
With completion of the Human Genome Project, 30,000–
35,000 genes have been mapped (6–9), each of which con-
tains the code for a specific product, typically a protein.
Through the proteins they encode, genes determine and regu-
late all human body processes. Human genomics includes a
continuum from the study of single-gene disorders with high
penetrance to common genetic variants or polymorphisms at
multiple loci, with low penetrance, and that have complex
gene-environment interactions (10). Genetic disorders are
caused by mutations, or alterations, in a gene or set of genes.
Mutations can be inherited or occur de novo. The effect of a
mutation on a gene depends on how it alters the expression or
function of the gene product and the role of that protein in
the body. Mutations in certain genes have severe effects,
whereas mutations in others do not.
The majority of genetic disorders result from a complex
interplay of multiple genetic changes and environmental fac-
tors. However, certain disorders result when a mutation alters
or causes an absence of the product of only one gene.
Examples of such single-gene disorders are cystic fibrosis (CF)
and phenylketonuria (PKU). Single-gene disorders can be
either X-linked (i.e., caused by a defect in a gene on the X
chromosome) or autosomal (i.e., caused by a defect in a gene
on an autosome or nonsex chromosome). Single-gene disor-
ders can result from either dominant or recessive patterns of
inheritance or expression. Selected chromosomal disorders,
which might be inherited, involve microdeletions of multiple
genes at closely linked loci. Although single-gene disorders
are individually rare, they collectively contribute to a substan-
tial proportion of pediatric morbidity and mortality (1).
PI diseases are a group of primarily single-gene disorders of
the immune system (11–13). Primary denotes the genetic
nature of the defects, differentiating them from secondary, or
acquired, immunodeficiencies caused by malnutrition, infec-
tion (e.g., human immunodeficiency virus [HIV] infection),
chemotherapy, or other external agents. Approximately 100
separate PI diseases have been described, but <20 probably
account for >90% of cases. The disorders vary in the severity
and spectrum of symptoms, but without effective and early
treatment, they can be fatal. A high index of suspicion and
prompt diagnosis can lead to lifesaving treatment and sub-
stantial improvement in quality of life for persons with PI
diseases. Causes of PI diseases vary, but single-gene defects
can lead to a missing enzyme, a missing structural compo-
nent, developmental arrest at a specific differential stage of
immune development, or a nonfunctional protein. As with
all single-gene disorders, selected PI diseases are known to be
X-linked or autosomal, with both dominant and recessive
patterns of inheritance or de novo mutations; others might
have more complex modes of inheritance not yet understood.
Approximately 80% of affected persons are aged <20 years,
and because certain PI diseases are inherited in X-linked
recessive fashion, 70% of cases occur among males (13).
Advances in human genomics have led to identification of
the gene defects responsible for >60 PI diseases and have
prompted development of new diagnostic and therapeutic tools
and potential gene therapies (14–20). New molecular tech-
niques have facilitated identification of different types of
mutations underlying PI diseases. Single-nucleotide substitu-
tions, or point mutations, involve an alteration in the sequence
of nucleotides in a gene. These include missense mutations,
which alter the amino acids in the protein product of a gene;
nonsense mutations, which generate premature stop codons
in the genetic code; RNA (ribonucleic acid) splice-site muta-
tions, which can lead to frameshift mutations; and regulatory
mutations, which affect aspects of gene expression. Mutations
also can involve insertions or deletions of DNA (deoxyribo-
nucleic acid) sequences. Progress in the delineation of the
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mechanisms by which these genetic mutations cause PI dis-
eases has added to the understanding of the normal immune
system and the processes that underlie conditions that occur
with far greater frequency than PI disease (21).
Clinical Characteristics and Effect
of PI Diseases
The clinical hallmark of PI diseases is an increased suscepti-
bility to infection, the severity of which varies by defect (13,22).
In certain cases, the body fails to produce any or sufficient
antibodies to fight infection. In other cases, the cellular (e.g.,
T-cell) defenses against infection fail to work properly. Shared
features of the disorders are an unusual rate or severity of
infection, infection with unusual or opportunistic organisms,
and infection associated with specific syndromes (13). PI dis-
eases also are associated with other immunologic disorders
(e.g., autoimmune diseases) and carry an increased risk for
cancer, particularly lymphoid malignancies (22). PI diseases
often are classified according to the affected components of
the immune system (Table 1).
Antibody Deficiencies
Approximately half of the diseases are associated with inad-
equate or defective antibody production, caused by too few
antibody-producing B cells or B cells that do not function
properly, resulting in inadequate production of antigen-
specific antibodies (23). These disorders are characterized by
recurrent sinus and pulmonary infections and septicemias with
bacteria (13,24). The most severe defect in this category is
X-linked agammaglobulinemia (XLA), typified by a limited
number or no mature B cells or antibody-secreting plasma
cells. Affected persons develop severe, recurrent bacterial
infections, usually during the first year of life.
Other antibody defects are common variable immunodefi-
ciency (CVID) and immunoglobulin A (IgA) deficiency.
CVID is characterized by variably low levels of immunoglo-
bulin G (IgG), immunoglobulin M (IgM), and IgA, and sub-
optimal antibody responses after vaccination. CVID patients
usually experience recurrent bouts of pneumonia and infec-
tions of the joints, bones, and skin. These persistent infec-
tions lead to organ damage, often resulting in disability or
death from chronic lung disease (25). Moreover, affected
females with CVID had a >400-fold increased risk for lym-
phomas in their fourth and fifth decades of life compared with
age-matched general population risks in one U.S. study (25).
IgA deficiency, similar to other PI diseases, has a wide clinical
spectrum. Although all affected persons lack IgA in the
mucous membranes lining the airways and digestive tract, cer-
tain persons are asymptomatic whereas other have recurrent
infections. For reasons not completely understood, the inci-
dence of allergy or autoimmune disease is increased among
patients with selective IgA deficiency. Certain IgA-
deficient persons might have severe or fatal anaphylactic
reactions to blood or blood-products containing IgA.
Combined B- and T-Cell Deficiencies
Combined B-cell and T-cell immunodeficiencies constitute
approximately 20% of PI diseases (23). In the most serious
forms (e.g., severe combined immunodeficiency [SCID] dis-
orders), survival beyond the first year of life is rare without
prompt immune reconstitution through hematopoietic stem
cell transplantation (15,16,19,26,27). Immune reconstitution
with gene therapy has been achieved for forms of SCID
(14,20). Early diagnosis of SCID is critical because the chances
for successful treatment are highest for infants who have not
yet experienced severe opportunistic infections (19). Muta-
tions in eight different genes cause SCID (19,28). Approxi-
mately half of all cases are linked to the X chromosome.
X-linked SCID results from a mutation in the interleukin 2
receptor gamma (IL2RG) gene that produces the common
gamma chain subunit, a component of multiple IL receptors.
The product of the IL2RG gene activates a key signaling mol-
ecule, Janus-associated kinase 3 (JAK3 gene product). A
mutation in JAK3 also can result in SCID. Other forms of
SCID are associated with deficient activity in the enzyme
adenosine deaminase (ADA gene product) or a defect in the
recombination-activating gene (RAG). The genetic defect has
not been identified for certain forms of SCID. Other com-
bined immunodeficiencies are part of well-defined immuno-
deficiency syndromes (e.g., Wiskott-Aldrich syndrome [WAS],
ataxia telangiectasia, and hyper-IgE syndrome), all of which
are associated with recurrent infections and decreased life
expectancy (Table 1).
Cellular immune deficiencies, resulting from defects in T-cell
maturation or function, contribute an estimated 10% of PI
cases (23). One example is DiGeorge syndrome, which is typi-
fied by aberrant development of the heart, parathyroid glands,
or thymus. The absence of a thymus gland in patients with
DiGeorge syndrome leads to low T-cell numbers and decreased
function, but the degree of immunologic impairment varies
considerably (29,30). Approximately 90% of these patients
have a microdeletion in chromosome 22q11.2, such that
multiple genes from this region are absent (additional infor-
mation is available at http://www.genetests.org).
Defective Phagocytes
An estimated 18% of PI cases result from defective phago-
cytes (23). Phagocytic defects result in the inability of cells
that normally engulf and kill invaders to remove pathogens or
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TABLE 1. Examples of primary immunodeficiency diseases, by affected component of the immune system
Mode of
Designation Gene Genetic locus inheritance Description/Pathogenesis
X-linked agammaglobu-
linemia (XLA)
Common variable
immunodeficiency (CVID)
ICOS deficiency
Immunoglobulin A (IgA)
deficiency
Hyper-IgM syndrome
type 2 (AID deficiency)
Hyper-IgM syndrome
type 3
DiGeorge syndrome
Interferon gamma
receptor deficiency
IL-12 receptor deficiency
X-linked SCID
Jak3 deficiency
IL7R deficiency
CD45 deficiency
BTK
Unknown
ICOS
IGAD1
AID
(AICDA)
CD40
DGCR
IFNGR1
IFNGR2
IL12B
IL12RB1
IL2RG
JAK3
IL7R
PTPRC
Xq21.3–q22
2q33
6p21.3
12p13
20q12–q13.2
22q11.2
6q23–q24
21q22.1–q22.2
5q31.1–q33.1
19p13.1
Xq13.1
19p13.1
5p13
1q31-q32
X-linked
recessive
Complex
Autosominal
dominant
with variable
penetrance
Autosomal
recessive
Autosomal
recessive
Autosomal
dominant
Autosomal
recessive
Autosomal
recessive
X-linked
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive/
Autosomal
dominant
Mutations in the gene encoding Bruton’s tyrosine kinase
(BTK), a regulator of B-cell development; absence of
mature circulating B cells and undetectable or substantially
low serum immunoglobulin (Ig) levels lead to recurrent
bacterial infections during the first year of life
Unknown variable defects in B- and T-cell function and
regulation result in recurrent bacterial infections, usually
during the second or third decade of life
One subset of CVID is ICOS deficiency, inducible host
stimulator defect
Absent or marked reduction of serum IgA; majority of
patients are asymptomatic; others have recurring
respiratory infections, chronic diarrhea, allergies, or
autoimmune disease
Defect in the activation-induced cytidine deaminase
(AICDA) required for Ig isotope switching and somatic
hypermutation in B cells; low IgG and IgA, normal or
increased IgM
Low IgG, IgA; normal or increased IgM; bacterial and
opportunistic infections
Hemizygous chromosomal deletion results in developmen-
tal defect of the thymus; also can cause congenital heart
disease, hypoparathyroidism, and other congenital defects
Autoimmune endocrinopathies; increased susceptibility to
mycobacterial disease
Defect in the receptor for interleukin-12; increased
susceptibility to mycobacterial disease
Most common form of SCID; caused by a mutation in the
IL-2 receptor gene on the X chromosome needed for the
normal growth and function of T cells and B cells;
lymphopenia occurs primarily from the absence or near
absence of T cells and natural killer cells; B cells are
immature and defective
Mutation in the gene that encodes Janus-associated
kinase 3 (JAK3) needed for differentiation of hematopoietic
cells; lymphopenia occurs primarily from the absence or
near absence of T cells and natural killer cells; B cells are
present but defective
Defect in the IL7 receptor needed for T-cell development;
T-cell numbers are low; B cells are present but nonfunc-
tional
Mutation in the protein tyrosine phosphatase receptor type
C CD45 gene results in a lack of expression of CD45; T-
cell numbers are low; B cells are present but defective
Antibody deficiencies
Cellular deficiencies
Combined B- and T-cell deficiencies
T-negative, B-positive — severe combined immunodeficiency (SCID): T cells are missing, but B cells can be present
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Other combined immunodeficiency syndromes
TABLE 1. (Continued) Examples of primary immunodeficiency diseases, by affected component of the immune system
Mode of
Designation Gene Genetic locus inheritance Description/Pathogenesis
RAG1 deficiency
RAG2 deficiency
Artemis deficiency
ADA deficiency
ZAP 70 deficiency
CD3 deficiency
PNP deficiency
X-linked hyper-IgM
syndrome
Wiskott-Aldrich
syndrome (WAS)
Ataxia-telangiectasia
Chronic mucocutaneous
candidiasis
Autoimmune
polyendocrinopathy with
candidiasis and
ectodermal dysplasia
(APECED)
X-linked lympho-
proliferative syndrome
Hyper-IgE syndrome
Ectodermal dysplasia
associated with immune
deficiency (EDA-ID)
RAG1
RAG2
Artemis
ADA
ZAP70
CD3E/G
PNP
CD40L
WASP
ATM
Unknown
CMCT
AIRE-1
SH2D1A
(SAP)
Unknown
IKBKG
(NEMO)
11p13
11p13
10p13
20q13.11
2q12
11q23
14q13
Xq26.3-
q27.1
Xp11.22-
Xp11.23
11q22.3
2p
21q22.3
Xq25
4q21
Xq28
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
X-linked
recessive
X-linked
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
dominant
Autosomal
recessive
X-linked
recessive
Autosomal
dominant
with variable
penetrance
X-linked
recessive
Mutations in recombinase-activating gene (RAG1) leads to
absence of mature B and T cells
Mutations in recombinase-activating gene (RAG2) leads to
absence of mature B and T cells
Mutation in the Artemis gene affects DNA recombination;
results in arrest of B- and T-cell development
Found in Athabascan-speaking people
Mutation in a gene encoding the enzyme adenosine
deaminase (ADA); lymphopenia occurs from the death of T
and B cells because of accumulation of toxic metabolites;
functional antibodies are decreased or absent
Mutation in ξ-associated protein of ZAP-70 kinase leads to
lack of expression of CD8 T cells and abundant CD4 cells
unresponsive to T-cell receptor-mediated stimuli
Absent CD3+ T cells result in recurrent infections in severe
cases
Defect in purine nucleoside phosphorylase (PNP) in the
purine salvage pathway; T-cell numbers are decreased
because of accumulation of toxic metabolites
Mutations in the CD40 ligand gene lead to impairment of
T-cell/B-cell interaction, lack of Ig isotope switching;
recurrent and opportunistic infections
Defect in cytoskeletal WAS protein (WASP), affecting
platelets and T cells, leads to thrombocytopenia, small
defective platelets, eczema, lymphomas, autoimmune
disease, and infections
Progressive multisystem disorder characterized by
neurologic impairment with ataxia, telangiectasia of the
conjunctiva and skin, malignancy, and radiation sensitivity
Chronic mucocutaneal candidal infections and autoimmune
endocrinopathies
Chronic mucocutaneal candidal infections with thyroid
disease
AIRE encodes a protein belonging to a family of transcrip-
tion factors
Uncontrolled lymphoproliferation induced by severe
Epstein-Barr virus (EBV) infections, B-cell lymphoma
Elevated IgE, with recurrent staphylococcal infections of
lung and skin
Molecular defect in NEMO causes impaired nuclear factor
kappa-beta (NF-kb) signaling; clinical syndrome includes
anhidrotic ectodermal dysplasia, conical teeth, atrichosis,
recurrent infections, and dysgammaglobulinemia
T-negative, B-negative — SCID: both T cells and B cells are missing
Other combined deficiencies
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Complement deficiencies
TABLE 1. (Continued) Examples of primary immunodeficiency diseases, by affected component of the immune system
Mode of
Designation Gene Genetic locus inheritance Description/Pathogenesis
Congenital neutropenia
Cyclic neutropenia
LAD1
LAD2
X-linked CGD
Autosomal recessive
CGD
Chédiak-Higashi
syndrome
Deficiency of individual
complement components
C1q, C1r, C1s, C2, C3,
C4, C5, C6, C7, C8, C9
Factor B, Factor H1
Unknown
ELASTASE2
ITGB2
FUCT1
CYBB
CYBA
NCF1
NCF2
CHS1
(LYST)
CIQA,
C1QB,
C1QG, C1R,
C15, C2, C3,
C4A, C4B,
C5, C6, C7,
C8A, C8B,
C8G, C9,
BF, HF1
19p13.3
21q22.3
11
Xp21.1
16q24
7q11.23
1q25
1q42.1-
q42.2
Various
Autosomal
recessive,
sporadic
Autosomal
recessive,
sporadic
Autosomal
recessive
Autosomal
recessive
X-linked
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Autosomal
recessive
Persistent neutropenia from birth
Neutropenia in 3–4-week cycles
Disorder of neutrophil adhesion caused by lack of CD18;
characterized by recurrent or progressive necrotic soft-
tissue infection, periodontitis, poor wound healing,
leukocytosis, and delayed umbilical cord detachment
Defect in GDP fucose transporter 1; associated with
mental retardation, soft-tissue infection, and delayed
healing
Disorder of white blood cell bactericidal function character-
ized by granulomatous lesions of the skin, lungs, and
lymph nodes; hypergammaglobulinemia; anemia; defective
killing of certain bacteria and fungi
All defects result in defective nicotinamide-adenine
dinucleotide phosphate (NADPH) oxidase
Defect in the lysosomal-trafficking regulator gene; results
in partial albinism, bleeding tendency, and fatal
lymphoproliferation from EBV; treatment is by bone-marrow
transplantation
Absence of complement components; results in increased
infections and lupus-like diseases; C1, C2, C3, C4
associated with autoimmunity and pyogenic infections
C5-C9 and properdin deficiencies associated with
neisserial infections
Phagocytic defects
Leukocyte adhesion defect (LAD)
Sources:
Anonymous. Autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc finger domains. Finnish-German APECED
Consortium. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal dystrophy. Nat Genet 1997;17:399–403.
IUIS Scientific Committee. Primary Immunodeficiency Diseases. Clin Exp Immunol 1999;118(Suppl 1):1–28.
Chapel H, Geha R, Rosen F. Primary immunodeficiency diseases; an update. Clin Exp Immunol 2003;132:9–15.
Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe
combined immune deficiency. Cell 2001;105:177–86.
Puck JM. Primary immunodeficiency diseases. JAMA 1997;278:1835–41.
Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome
(HIGM2). Cell 2000;102:541–4.
Smith CIE, Ochs HD, Puck JM. Genetically determined immunodeficiency diseases: a perspective. In: Ochs HD, Smith CIE, Puck JM, eds. Primary
immunodeficiency diseases: a molecular and genetic approach. New York, NY: Oxford University Press, 1999.
National Center for Biotechnology Information. OMIM™ Online Mendelian Inheritance in Man. Bethesda, MD: National Library of Medicine, 2000. Available
at http://www.ncbi.nlm.nih.gov/omim.
Chronic granulomatous disease (CGD)
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infected cells from the body. Chronic granulomatous disease
(CGD), caused by a defect in intracellular killing of bacteria
by phagocytes, usually appears in childhood, but milder forms
can appear in the second or third decade of life. It can be
inherited as an X-linked or autosomal-recessive defect; affected
persons experience frequent and severe infections of the skin,
lungs, and bones and tumor-like masses called granulomas.
In leukocyte adhesion defect (LAD), phagocytes lack an
essential adhesion molecule, preventing them from migrating
to sites of infection. The result is recurrent, life-threatening
infections, especially of the soft tissues. Chédiak-Higashi syn-
drome is a rare and usually fatal disorder caused by granule
defects in phagocytes, platelets, and melanocytes. Patients have
partial oculocutaneous albinism and often experience over-
whelming and fatal infections with Epstein-Barr virus. Both
LAD and Chédiak-Higashi syndrome are inherited as
autosomal-recessive defects.
Complement System Defects
Defects in the complement system occur less frequently than
other PI diseases. They are associated with a nonfunctional
protein or the absence of a complete complement molecule
capable of attaching to antibody-coated foreign invaders and
opsonizing bacteria. The most common defect, C2 deficiency,
is an autosomal-recessive inherited defect in the gene for the
complement protein C2. Affected persons have recurrent and
severe infections with encapsulated bacteria, frequently men-
ingitis, and a susceptibility to autoimmune diseases. Terminal
complement protein (C6-8) deficiencies are associated with
severe infections with Neisseria meningitidis and N. gonorrhoeae.
Prognoses for Patients with PI Diseases
Although PI diseases share selected clinical manifestations,
both the timing of the onset of symptoms and the prognosis
vary considerably. Patients with antibody or complement
deficiencies can have near-normal life spans, if their deficien-
cies are diagnosed early, managed appropriately, and are not
affected by concurrent chronic diseases. Persons with phago-
cytic disorders, combined immunodeficiency disorders, and
antibody disorders with chronic infections have guarded prog-
noses; the majority are chronically ill and require intensive
treatment. Certain severe PI diseases (e.g., SCID) become
apparent early in life, with only a short asymptomatic period
after birth. Without an effective early intervention, the
majority result in death during the first years of life.
Incidence and Birth Prevalence
Estimates
The true frequency of PI diseases in the general population,
either individually or in the aggregate, has not been ascer-
tained, but estimates have been reported. Certain countries
have developed registries to collect information regarding cases
of PI diseases (31–36). The minimum prevalence of PI has
been estimated by using data collected from these registries.
At least five factors cause these registries to underestimate the
true prevalence of PI diseases: 1) lack of clinical recognition,
2) lack of reporting to the registries, 3) overrepresentation of
certain referral centers, 4) lack of a standardized case defini-
tion, and 5) death before recognition. Population-based data
related to incidence and prevalence are critically needed.
The reported minimal estimate of birth prevalence of SCID
based on recognized cases is 1/100,000, but this under-
estimates the prevalence because of infant deaths occurring
before diagnosis (15). In contrast, selective IgA deficiency, the
most common immunodeficiency, was found in as many as
1/328 healthy blood donors (37). In aggregate, the estimated
incidence of diagnosed PI diseases has been reported as
1/10,000 persons (22,38,39). As a comparison, incidence
estimates for CF are 1/2,500 among whites and for PKU are
1/16,000 persons (40,41).
Diagnosis
Early detection is possible for the majority of PI diseases, is
critical for the success of certain therapies, and can be life-
saving. Genetic diseases (e.g., single-gene disorders with high
penetrance) can be detected along a continuum of symptom-
atic expression by using 1) screening tests to evaluate asymp-
tomatic newborns for conditions that require early intervention
and 2) clinical algorithms for early recognition of symptom-
atic persons before the onset of clinical morbidity, with con-
firmatory laboratory diagnosis (including genetic testing)
(Figure 1). Effective treatment regimens then can be initiated
early in the course of disease to reduce morbidity, disability,
and mortality.
The first clinical clue in diagnosis of a PI disease is usually a
history of infections that are persistent, recurrent, difficult to
treat, or caused by unusual microbes. Because PIs are frequently
inherited, a positive family history is also a key diagnostic tool
(42); in a series of 70 PI patients identified in an immunology
clinic, 18.6% (N = 13) had family histories of immunodefi-
ciency (43). The type of infection identified in either the
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patient or the family history also might indicate the nature of
an immunodeficiency. Infections with bacterial organisms are
frequently observed among patients with antibody deficien-
cies; severe infections from viruses, fungi, and other opportu-
nistic organisms characterize T-cell immunodeficiencies.
Recurrent infections with staphylococcal and other catalase-
positive organisms indicate phagocytic defects, and recurrent
Streptococcus pneumoniae or Neisseria infections characterize
patients with complement deficiencies.
Physical examination can identify characteristic physical
findings and anatomic changes secondary to infections.
Patients with PI diseases often appear chronically ill, with pal-
lor, malaise, and a distended abdomen caused by hepatosple-
nomegaly. Patients with XLA typically lack peripheral lymph
nodes, adenoids, and tonsils. Lymphadenopathy is observed
frequently among patients with CGD. In WAS, the genetic
mutation causes thrombocytopenia as well as immune defects;
children have bruising, petechiae, and eczematous rash (44).
However, clinical symptoms can vary from patient to patient,
even for identical mutations of the same gene (45). Typical
radiographic findings include an absent thymus, which is the
hallmark of DiGeorge syndrome and multiple types of SCID.
Children with infant-onset ADA deficiency often have char-
acteristic skeletal abnormalities of the ribs and hips readily
apparent on radiograph.
Laboratory tests are required to diagnose a PI disease (46).
No single testing modality is appropriate for all situations.
Given that certain PI diseases have overlapping features and
that selected ones can be caused by combined immune defects,
clinicians advocate a stepwise approach to screening the
immune system (Figure 2). The majority of initial tests are
available through commercial or hospital laboratories and
include tests to assess humoral immunity (i.e., Ig proteins and
specific antibodies), cellular immunity (e.g., lymphocyte/
mononuclear cell quantitation or functional assays), phago-
cytic cell function, and complement components and function.
Genetic testing involves “analysis of human DNA, RNA,
chromosomes, proteins, and certain metabolites to detect heri-
table disease-related genotypes, mutations, phenotypes or
karyotypes for clinical purposes” (47). In cases for which the
location of the genetic defect is known, testing involves direct
testing of the patient’s DNA to identify specific mutations. In
certain cases, an assay to measure mRNA (messenger RNA)
(e.g., polymerase chain reaction [PCR]) or the protein prod-
uct (e.g., immunoblotting or flow cytometry) can confirm a
diagnosis when the gene product is absent; however, this
method cannot detect disease associated with a nonfunctional
protein. A simple, reliable way to evaluate function for T cells
is delayed type hypersensitivity skin tests and for B cells,
antibody responses after vaccination.
Treatment
Interventions for PI diseases are aimed at preventing infec-
tion, prolonging life, and improving quality of life (48). Use
of antibiotics to treat and prevent infections is a key element
in patient management. In certain cases, prophylactic antibi-
otics help to prevent infections (e.g., trimethoprim-
sulfamethoxazole to prevent Pneumocystis carinii pneumonia
among patients with T-cell defects and prevent recurrent
infections among patients with CGD). Research has demon-
strated the safety and efficacy of replacement therapy with
intravenous Ig (IVIG) among patients with defects in anti-
body production (49). Enzyme replacement therapy for ADA
deficiency also is effective (50). Curative interventions, pri-
marily bone-marrow and stem-cell transplantation, have been
used with varying degrees of success for an expanding array of
PI diseases (15,16,19,26,27,51,52). Clinical trials also have
demonstrated that gene therapy can restore near-normal
immune function among patients with SCID caused by
mutations in IL2RG, and similar types of therapy are promis-
ing for other immunodeficiencies (14,17,20). However,
recently, the occurrence of T-cell leukemia in two of 10 chil-
dren administered gene therapy for IL2RG SCID (mutant
gamma-chain IL-2 receptor) has prompted a halt to all gene
therapy using retroviral vectors for immunodeficiency. In these
cases, the retroviral gene construct of the IL2RG gene inserted
itself on the oncogene LMO2 that is aberrantly expressed in
acute lymphocytic leukemia of childhood. Thus, insertional
oncogenesis was the probable cause of the T-cell leukemia in
these two cases (53–55).
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FIGURE 2. A diagnostic testing algorithm for primary immunodeficiency diseases
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Public Health Framework
The defining characteristics of PI diseases make them can-
didates for a public health intervention approach. Although
the clinical manifestations and underlying genetic defects are
diverse, PI diseases share the common feature of increased
susceptibility to infection and collectively result in substantial
morbidity and shortened life spans. Most important, prompt
diagnosis and treatment can be life-saving and result in marked
improvements in the quality and length of life.
The foundation for a public health intervention to improve
the health status of persons with PI diseases is population-
based information regarding the incidence, prevalence, and
natural history of the diseases; the accuracy of diagnostic meth-
ods; and the efficacy of early interventions. However, the
majority of these data are lacking. The heterogeneity of PI
diseases and the limited understanding of the relation between
genotype and phenotype also hinder intervention efforts. Addi-
tional obstacles include the difficulty of diagnosis in the
absence of a high index of suspicion and the lack of awareness
among health-care providers and the public, which impedes
the timely recognition of affected persons by using a combi-
nation of clinical suspicion and diagnostic testing.
To address these impediments and improve health outcomes
among persons with PI diseases, CDC and partners have
adapted a population-based public health framework devel-
oped as part of CDC’s strategic plan for genomics and public
health, to the problem of PI diseases (56). The framework has
four components as follows:
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• public health assessment — application of traditional
public health methods to assess the impact of PI diseases
on community health;
• population-based interventions — development, imple-
mentation, and evaluation of screening tests administered
to newborns and clinical algorithms for early recognition
of symptomatic persons to facilitate the earliest possible
diagnosis and treatment for PI diseases;
• evaluation of screening and diagnostic tools — evalua-
tion of screening and diagnostic tools to ensure their qual-
ity and appropriateness for identification of patients with
PI diseases; and
• communication — communication with health-care
providers and the public to facilitate prompt and
appropriate diagnosis and intervention.
CDC has begun to apply this framework in the context of
ethical, legal, and social considerations to different conditions,
most recently to hereditary hemachromatosis, a treatable,
adult-onset, single-gene disorder of iron metabolism (57–61).
For example, gaps in data related to the natural history of the
disease, penetrance, optimal treatment for asymptomatic per-
sons, and the psychosocial effect of genetic testing precluded
recommendations for population screening for mutations in
HFE, the associated gene (62–64). However, educational
efforts are under way to facilitate early diagnosis (e.g., iron
overload and HFE mutation testing). Lessons learned from
applying the framework to hemochromatosis is being applied
to other conditions, including PI diseases.
In November 2001, CDC convened a multidisciplinary
panel of specialists to identify and discuss public health strat-
egies that can be applied to PI diseases and also used as an
approach for other genetic disorders (65). A systematic assess-
ment based on the established public health framework was
applied to the growing group of recognized PI diseases, for
which diverse genetic mutations span multiple components
of the immune system but all lead to the increased incidence
and severity of infections. During the meeting, specialists in
clinical immunology, public health, genetics, pediatrics, health
communication, and ethics from state and federal agencies,
academic centers, professional organizations, and advocacy
foundations discussed the public health framework as it
relates to PI diseases. The working group’s deliberations were
organized around the four components of the framework and
centered on challenges and opportunities, priority research
questions, and recommendations for public health action. The
remainder of this report reflects their analysis of the problem,
their conclusions and recommendations, and subsequent
deliberations and findings.
Public Health Assessment
Assessment Tools
The majority of what is understood regarding PI diseases
derives from accumulation of data from clinical case reports,
case series, and case registries. This approach has advantages
but has not provided a complete understanding of the inci-
dence, prevalence, and natural history of PI diseases. A public
health assessment of the magnitude and characteristics of the
problem in the United States, using population-based data, is
needed. Quantitative public health methods can be used to
assess the effect of gene variants on the risk for disease, dis-
ability, and death and to determine the impact of population-
based interventions on improved health outcomes. The
traditional tools of public health assessment are 1) surveil-
lance, 2) epidemiology, and 3) laboratory science.
Surveillance Systems. Surveillance is the systematic collec-
tion, analysis, and interpretation of data related to health out-
comes and other health-care events for use in planning,
implementation, and evaluation of population-based health
activities (66,67). Surveillance data can be derived from tra-
ditional data sets (e.g., vital records and health surveys) or
obtained proactively from health-care providers, health-care
institutions with electronic patient records, or laboratories.
Effective surveillance requires standardized case definitions for
each disorder of interest.
A surveillance system for PI diseases should be used to
determine the incidence and prevalence of these conditions.
Assuming routine performance of genotyping, a laboratory-
based surveillance component should facilitate the calcula-
tion of the prevalence of gene variants among cases. The ability
to link cases with other data sets will help determine the mor-
bidity, mortality, disability, and health-care costs associated
with PI diseases and help set priorities based on public health
impact. The availability of outcomes data will allow evalua-
tion of the effect of changes in health-care policy and practice.
Epidemiologic Research. Epidemiology is the study of the
distribution and determinants of disease in specified popula-
tions, including assessment of the causal effect of preventive
interventions on health outcomes. Although clinical research
can identify gene variants and other risk factors for PI dis-
eases, population-based analytic epidemiologic studies are
needed to quantify the effect of gene variants on the risk for
disease, death, and disability and to determine the relations
between genotype and phenotype in the population (1). Epi-
demiologic studies that contribute to the understanding of
the natural history and clinical course of PI diseases and the
benefits of early detection and intervention can improve indi-
vidual outcomes and reduce the public health burden of this
group of diseases. Epidemiologic research methods also are
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needed to assess the determinants and uses of genetic testing
and other promising interventions and health-care practices.
Laboratory Science. Both surveillance and epidemiologic
research are conducted in conjunction with laboratory efforts.
These center on diagnostics, phenotypic characterization, ge-
netic analysis, studies of genotype-phenotype relations, and
development and evaluation of screening and diagnostic tests.
Existing Data-Collection Systems
Existing population-based data from which to derive a public
health assessment of PI diseases are limited. Available data
are derived from case-based disease registries that collect pa-
tient-specific information from multiple sources.
Disease and Mutation Registries. Case-based registries usu-
ally are designed to improve patient care but can be helpful
for studying rare diseases. In 1992, the Immune Deficiency
Foundation (IDF) initiated a registry of U.S. patients with
CGD and 5 years later expanded the project to include seven
other disorders — hyper-IgM syndrome, XLA, CVID, WAS,
SCID, LAD, and DiGeorge syndrome (36). The most reli-
able data from these registries are for CGD, for which IDF
has calculated a minimum estimated U.S. incidence of
1/200,000 live-born infants (36). The registry also is used to
collect data related to natural history and clinical course,
including the response to treatment. In 1995, IDF conducted
a national, cross-sectional survey of approximately 17,000
immunologists and medical school faculty to estimate the bur-
den of PI diseases in the United States, to describe character-
istics of persons with these disorders, and to identify problems
related to access to treatment. Approximately 1,500 physi-
cians reported caring for an estimated 21,000 patients with
PI disease (68).
Other countries have developed their own registry-based
estimates of the frequency of PI diseases, ranging from an
estimated prevalence of 2.1/100,000 in Australia (31) to 6.8/
100,000 in Norway (32–34). A registry maintained by the
European Society for Immunodeficiencies (ESID) collects data
regarding patients from approximately 25 countries in
Europe (69). As of July 2000, the ESID registry contained
clinical data for approximately 8,900 patients from 26 coun-
tries (70). An example of a registry for another genetic disor-
der that might be a model for PI diseases is the CF registry,
which is based on case ascertainment at comprehensive treat-
ment centers. The Cystic Fibrosis Foundation (CFF) spon-
sors the National Cystic Fibrosis Patient Registry to collect
data regarding all patients examined at CFF-supported and
accredited care centers (71). Data are used to support epide-
miologic studies, direct research, and design clinical trials, all
with the goal of improving the survival of persons with CF
(72).
Other sources of case-based information are the Internet-
based, locus-specific immunodeficiency mutation databases
established by ESID and expanded by other investigators
(73,74). These databases contain information regarding spe-
cific mutations and certain clinical features of affected per-
sons. The first Internet-based immunodeficiency mutation
database, BTKbase, was initiated in 1995 to collect informa-
tion related to mutations in the BTK gene (Bruton’s tyrosine
kinase), which causes XLA (75). Similar locus-specific muta-
tion databases have been developed since then (69,73). Muta-
tion databases can be used to analyze the types of mutations
and their distribution in exons and introns, including their
location in protein domains. Mutation databases that contain
clinical information can be helpful in assessing genotype-
phenotype relations and determining the presence of gene
variants in asymptomatic family members (76).
Data from disease and mutation registries can be used to
estimate the minimal incidence of a disorder, characterize epi-
demiologic features, and define a range of clinical characteris-
tics in a cohort of patients (36). However, although each has
its applications, current registries provide incomplete
population-based data regarding the burden of PI diseases.
Continued growth of disease and mutation registries relies on
the submission of case reports by physicians, resulting in
overrepresentation of certain clinical centers in the sample
collection (59). Incomplete ascertainment limits the repre-
sentativeness of the data. Moreover, the lack of standardized
case definitions precludes the calculation of sound population-
based rates from these sources. The value of mutation data-
bases for public health assessment also is limited by the rarity
of genetic laboratory confirmation of PI diagnoses. In other
cases, the mutated sequence might be known but not submit-
ted to the database.
Population-Based Morbidity and Mortality Data. To con-
tribute to the study of the impact of single-gene disorders,
existing population-based data sources were reviewed. Sur-
veillance databases already have been used to evaluate the
impact of hereditary hemochromatosis (59). Hospital discharge
data provide information concerning short-stay hospitaliza-
tions for specific conditions and have been used, for example,
to document the substantial morbidity rate and hospitaliza-
tion charges associated with birth defects and genetic diseases
among children (57,77,78). However, the national hospital
discharge survey enumerates hospital discharges rather than
individual patients, and for rare or underdiagnosed diseases
might provide more limited information because of potential
inaccuracy of coding and duplication caused by multiple hos-
pitalizations for the same patient. Managed care organizations
maintain substantial, linked, computerized inpatient and
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outpatient databases that can be helpful in determining inci-
dence rates (79). One example is the Vaccine Safety Datalink
(VSD), a partnership between CDC and four health-
maintenance organizations designed to evaluate vaccine safety
among children. Computerized data concerning vaccinations,
medical outcomes, and health services usage are provided for
a well-defined population of approximately 1 million chil-
dren (1993–1996). In addition to determining vaccine-
related adverse events, this database could be examined for
other relatively infrequent events, including PI diseases (78–80).
Mortality data can provide population-based information
concerning survival and cause-specific mortality regarding
genetic disorders (60,81–83). Since 1968, CDC’s National
Center for Health Statistics has compiled data from all death
certificates filed in the United States and made these data avail-
able in Multiple-Cause Mortality Files (82,84). The files
include demographic and geographic information regarding
the decedent and International Classification of Disease (ICD)
codes for the underlying cause of death and <20 conditions
listed on the death certificate (85,86). Methodologic limita-
tions include reliance on coding systems that are not unique
or specific enough for birth defects and genetic diseases; delay
between death and availability of data; and limited informa-
tion regarding risk factors. Despite these limitations, mortal-
ity files and other population-based data sources will be critical
for planning interventions for PI diseases, especially as the
causes and treatments of these disorders are further elucidated
by epidemiologic studies and human genome research
(75,87,88).
Population-Based Disease Surveillance. Efforts to collect
population-based epidemiologic and surveillance data related
to patients with other genetic diseases also might be helpful
models for assessment of PI diseases. Population-based birth-
defects surveillance systems also hold promise for collection
of data regarding PI diseases (87). Each state has a different
approach to birth-defects surveillance. Data sources include
vital records, hospital and clinic records, and administrative
databases. The diversity of approaches — particularly meth-
odologies used to generate timely data, applications to moni-
tor prevention activities, and projects to improve access to
health services and early intervention — provides useful
resources for developing surveillance systems for other child-
hood diseases.
CDC’s program to prevent complications from hemophilia
and other bleeding and clotting disorders includes a national
surveillance system, prevention interventions conducted
through a nationwide network of hemophilia treatment cen-
ters (HTCs), and epidemiologic and prevention research.
CDC’s first state-based surveillance effort was designed to
identify all patients with hemophilia in six states, characterize
the patient population, and identify risk factors and outcomes
of care (89,90). Through this effort, CDC derived the first
population-based estimate of hemophilia prevalence in the
United States and demonstrated the effectiveness of the HTC
model. In 1996, to address gaps in this system (e.g., lack of
patient follow-up and specimen collection), CDC and the
HTCs initiated a prospective universal data collection (UDC)
system. The UDC system is designed to guide clinical prac-
tice, monitor blood safety, develop a specimen repository, and
monitor the clinical extent and progression of joint disease
(91). Although the UDC system is more comprehensive than
the initial surveillance effort, the requirement for informed
consent might affect its population-based representativeness.
Workshop Recommendations for Action. The goal of public
health assessment for PI diseases is to collect population-based
data to define the incidence and prevalence of the disorders.
Recommendations from the workshop for public health
assessment for PI diseases include the following:
• Collect population-based data regarding the incidence,
prevalence, and natural history of PI diseases.
• Collect population-based data regarding the relations
between genotype and phenotype for these diseases.
• Collect population-based data regarding the effect of early
recognition and effective therapies on morbidity and
mortality.
• Target three subsets of PI diseases as priorities for a
systematic public health assessment; possibilities include
— profound T-cell defects, because of their resulting high
mortality in the absence of interventions;
— antibody deficiencies, because of the substantial
number of persons affected and the high burden of
morbidity; and
— CGD, because of the existence of an established IDF
data set.
• Conduct pilot activities to improve the collection, use,
and quality of surveillance and epidemiologic data. These
might include
— convening a working group of clinical immunologists
and scientists to provide guidance regarding case defi-
nitions for registry and surveillance activities;
— developing collaborations between public and private
advocacy groups to expand data collection and com-
pleteness of disease registries and to conduct further
analyses;
— exploring use of existing population-based databases
for their potential in yielding useful information
regarding the incidence, prevalence, and natural
history of PI diseases; and
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— developing collaborative state-based surveillance activi-
ties for genetic diseases, including PI diseases. For the
short term, these might include implementing pilot
surveillance systems, similar to birth-defects surveil-
lance, in states with large population sizes because of
the estimated rare incidence of these diseases. In addi-
tion, linking surveillance to existing databases should
be explored (e.g., Vaccine Safety Datalink, hospital-
discharge data, IDF registry, or laboratory-based
reporting). In the future, surveillance can be expanded
beyond the pilot states.
• Participate in ICD revisions to promote development of
unique and specific codes for PI diseases.
• Promote development of a network of centers of excel-
lence, and encourage the use of these centers for epide-
miologic data collection, specimen repository, and special
studies. Possibilities for special studies are longitudinal
spectrum-of-disease studies, clinical trials, and evaluations
of genotype/phenotype relations.
Population-Based Interventions
Two major areas were discussed at the workshop, 1) early
clinical recognition of PI diseases and 2) newborn screening.
Early Clinical Recognition
Background and Rationale. Timely and effective
population-based interventions can reduce morbidity and
mortality from genetic diseases (Figure 1). For PI diseases,
these interventions center on early diagnosis and implemen-
tation of effective therapy (e.g., hematopoietic stem cell trans-
plantation, Ig replacement, and administration of antibiotics).
The intervention component of the public health framework
for PI diseases therefore involves development of strategies for
early diagnosis, implementation of pilot demonstration
projects, and evaluation of the effect of these interventions on
morbidity, disability, health-care costs, and mortality.
When evidence indicates that early diagnosis and treatment
will avert the late stages of disease and prevent morbidity, dis-
ability, and premature mortality, increased early clinical rec-
ognition is one component of a public health response. The
goal is to identify persons who have early symptoms indica-
tive of a PI disease so they can receive diagnostic testing to
confirm the presence or absence of disease and receive appro-
priate interventions to prevent adverse outcomes. Although
data regarding the benefits of early symptomatic screening are
limited, information from clinical centers supports improved
outcomes for certain PI diseases through early intervention
(25,92–94). The effect might vary, depending on the genetic
defect, the age at diagnosis, presence of prior infections, and
history of vaccination and blood transfusion (93).
Symptom-Based Screening — Clinical Algorithm.
Increasing early symptomatic screening for PI diseases
requires concerted efforts to increase awareness of these con-
ditions among physicians and health-care systems. Primary-
care clinicians, particularly pediatricians and family practice
physicians, provide the first point of contact for persons with
PI diseases by recognizing the possibility of an immunologic
problem and the need for appropriate evaluation. Clinicians
need to be aware of the estimated prevalence of PI diseases,
the natural history of the disorders, the availability and effi-
cacy of treatment, and most importantly, the common early
symptoms. Early recognition of PI diseases in the clinical set-
ting can be facilitated by development and evaluation of a
symptom-based screening algorithm. Such an algorithm can
be designed to 1) identify persons with a frequency of infec-
tions who fall outside the normal range of infections;
2) increase physicians’ awareness of the types, frequency, and
appearances of PI diseases; 3) facilitate physicians’ understand-
ing of useful screening approaches (e.g., family history); and
4) trigger appropriate action without overburdening the
medical care system.
The enhanced early clinical recognition approach has mul-
tiple advantages. Symptom-based screening occurs in the usual
health-care setting and requires no additional screening infra-
structure. Although certain children and adults seen in
primary-care settings might have clinical symptoms suggest-
ing PI disease, the number tested still will be considerably
lower than that required for universal screening. Finally,
including a PI disease as a suspected diagnosis will occur in a
clinical setting that offers options for follow-up and referral.
However, the benefits of the symptom-based approach will
be limited if diagnostic testing and treatment are unavailable
or delayed. For example, researchers at Mt. Sinai School of
Medicine are studying whether PI diseases are underrecognized
among minority and economically disadvantaged persons. The
percentage of white non-Hispanic patients among whom PI
diseases are diagnosed and treated at Mt. Sinai is dispropor-
tionately high (92%), compared with the population of the
hospital’s catchment area of East Harlem, which is predomi-
nately Hispanic (52%) and black non-Hispanic (37%). Pos-
sible reasons for the disparity include receipt of care in
emergency departments and clinics with multiple providers,
lack of regular contact with a primary-care physician, and lack
of continuity of care. Investigators are evaluating use of pro-
files of diagnostic codes that might indicate probable PI dis-
eases and help providers identify patients earlier. Improvements
in the specificity and accuracy of coding have been identified
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as needs. Mt. Sinai also is undertaking outreach and educa-
tional efforts directed toward providers serving minority popu-
lations to increase their awareness and improve the timely
diagnosis of PI diseases (65). Such efforts at other centers and
in a population-based approach might substantially affect the
care of patients with PI diseases.
Assessment and Evaluation of Impact. Initiation of treat-
ment after identification of a PI disease and early in the course
of disease might be sufficient to prevent premature mortality,
but a patient’s quality of life will not improve if the sequelae
are not reversible or the disease progression cannot be halted.
Thus, systematic studies of the natural history of disease and
the effectiveness of interventions in modifying health outcomes
are critical. In addition, if the clinical validity of an early rec-
ognition algorithm is not sufficiently sensitive, cases will be
missed; if the algorithm is not specific enough, too many per-
sons will be referred for testing. Proposed algorithms there-
fore need to be assessed for analytic validity (e.g., comparing
the number and type of infections reported by patients to the
documentation in the medical record), clinical validity (e.g.,
determining the proportion of persons with specific symp-
toms who have or do not have a PI disease), and clinical util-
ity (e.g., determining whether early detection of a specific
disorder affects long-term outcomes and is cost-effective).
The limited experience with symptom-based screening
methods for a group of diverse disorders demonstrates the
challenges in establishing clinical algorithms that can be
applied readily in busy clinical practices with accuracy and
efficiency (43,95). Findings indicate that clinical algorithms
vary in their analytic and clinical validity, especially depend-
ing on the age of the population. Therefore, algorithms must
be refined to improve sensitivity and avoid missed cases and
to increase specificity to reduce costs associated with the
immunologic workup of unaffected children and adults. New
practice parameters, including information related to diagno-
sis and treatment, are in development, and physicians need to
be made aware of these to assist in the early identification and
management of these patients (L. Kobrynski, M.D., Emory
University, Atlanta, Georgia, personal communication, 2003).
Workshop Recommendations for Action. Different
approaches for early clinical recognition have been used in
clinical settings, but none have been systematically evaluated.
Workshop recommendations for early clinical recognition are
as follows:
• Collect data related to the effect of early interventions on
morbidity and mortality associated with PI diseases.
• Identify a group of diseases that can benefit from using
an early clinical recognition algorithm. Possibilities
include SCID, XLA, CVID, CGD, and WAS.
• Establish a working group to create a system of clinical
algorithms for early clinical recognition of PI diseases. The
working group should include primary-care physicians.
Possible early-recognition tools are scoring systems, lists
of warning signs, questionnaires, or alert bulletins.
• Select target audiences and adjust the early-recognition
tools for each audience.
• Before widespread application of the algorithms, evaluate
the usefulness and accuracy of early clinical signs and
symptoms and initial laboratory tests for early recogni-
tion of PI diseases. Explore existing databases to test
proposed algorithms.
• Report on the effectiveness of the tools among the origi-
nal target audiences and amend the tools as indicated.
• Evaluate the usefulness of family history in recognizing
single-gene disorders early.
• Conduct collaborative studies among clinical centers to
examine the natural history of selected PI diseases.
• Conduct research regarding impediments to access to treat-
ment and case management.
• Conduct needs assessments related to timely diagnosis,
access to treatment, and ongoing care.
Newborn Screening
Certain severe PI diseases become apparent early in life, with
only a short asymptomatic period after birth. Without an
effective intervention, the majority result in irreversible com-
plications and death before the end of the first year of life.
The most useful method for improving the outcomes of dis-
eases with such a narrow window for detection and interven-
tion might be population-based newborn screening (NBS).
Existing Newborn Screening Programs. NBS programs
began in the 1960s with the development of an accurate and
sensitive test for PKU, an inherited disorder of metabolism
(96). Children affected with PKU are unable to metabolize
the amino acid phenylalanine. If untreated, affected children
will be severely mentally retarded and experience other neu-
rologic symptoms. However, dietary therapy started soon
after birth will reduce symptoms and allow affected children
to develop normally. The average incidence of PKU is
approximately 1/16,000 births.
The PKU assay uses a dried blood spot (DBS) specimen.
Blood is collected from the heel of an infant 1–2 days after
birth. The heel is pricked, and a few drops of blood are spot-
ted onto a filter paper card, dried, and sent to a state or
regional public health laboratory. Small filter-paper disks con-
taining dried blood are punched from the specimens and used
to test the newborn for PKU and other disorders. This simple,
easily transported, and inexpensive specimen-collection
method has led to development of population-based
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screening of newborns throughout the world (41,97–99).
Babies in the United States are screened for 4–30 different
metabolic, hematologic, and endocrinologic disorders within
a few days of birth. All of these tests are performed by using
DBS specimens. As a population-based public health activity,
NBS programs are the responsibility of state public health
agencies and operate under policies determined at the state
level, although laboratory screening might be contracted to
other states or to academic or private laboratories (97,100).
Newborn Screening Quality Assurance Program. CDC’s
Newborn Screening Quality Assurance Program (NSQAP)
produces, certifies, and distributes DBS materials for external
quality control and performance surveillance to help NBS labo-
ratories evaluate and improve the quality of their testing and
to foster standardization of NBS services (101). Approximately
250 national and international screening laboratories from
45 countries participate in the quality assurance program.
NSQAP recently added quality assurance materials for disor-
ders detected by tandem mass spectrometry (102,103) and
CF (101).
Principles for Evaluating Evidence for Newborn
Screening. Guidelines for NBS programs are linked to ethi-
cal, legal, and social considerations and are based on the
premise that screening should be conducted only when sci-
ence and technology can serve both the individual person and
the public good. Certain landmark reports (47,98,104) iden-
tify criteria for population-based NBS programs. The criteria
typically follow standard principles of population screening
developed in 1968 (105). These principles emphasize the
• importance of a specific condition to public health;
• availability of an effective screening test;
• availability of diagnosis and treatment;
• existence of a recognizable latent or early symptomatic
phase for the condition and an adequately understood
natural history;
• an agreed upon policy regarding whom to treat;
• a balance between screening costs and health expendi-
tures; and
• availability of case-finding capabilities.
These criteria have been discussed and modified multiple
times (64,100). With the advent of new testing technologies,
the criteria and corresponding evidence and ethical problems
are being revisited at the state and national levels (64).
Newborn Screening and SCID. Among PI diseases, SCID
is a candidate for development of an NBS protocol. SCID is
characterized by profound deficiencies of T- and B-cell func-
tion and is usually lethal during infancy without successful
immune reconstitution, ideally during the first months of life
(15,16,19).
Efficacy of Early Identification and Treatment. Research
indicates that infants with SCID who receive hematopoietic
stem-cell transplants from related donors in the first 3.5
months of life have approximately 95% chance of survival,
compared with a survival rate of 76% for infants receiving
this treatment after 3.5 months (27). Infants who received
stem cell transplants during the first 28 days of life demon-
strated higher levels of T-cell reconstitution and thymic out-
put than did those who received a transplant later; updated
survival estimates were 95% (N = 21/22) for infants receiving
transplants during the first 28 days, compared with 74%
(N = 71/96) for infants receiving transplants after the neona-
tal period (19). An analysis of registry data for 475 SCID
patients from 37 centers in 18 European countries reported
that long-term survival among patients who received stem-
cell transplants has improved, probably because of more
effective prevention of complications (106). Differences were
identified by SCID phenotype, with poorer outcomes
occurring among SCID patients without B cells than among
those with B cells. Immune reconstitution using gene therapy
in clinical trials has also been achieved for forms of SCID
(14,17,18,20,52); however, as discussed previously, the unex-
pected complication of T-cell leukemia occurred among 2 of
10 children receiving therapy for IL2RG SCID (53–55). Simi-
lar types of therapy are promising for other immunodeficien-
cies (26).
The need to identify at birth children with SCID, as evi-
denced from clinical studies, permits time to institute thera-
pies for immune reconstitution before the onset of
opportunistic and other infections associated with negative
outcomes. SCID meets certain traditional criteria for NBS, as
follows (105):
• SCID is fatal during infancy without immune reconsti-
tution.
• A short asymptomatic period exists after birth.
• Effective treatments are available.
• Early intervention improves outcome.
• Profound deficiencies of cellular and humoral immunity
might be detectable with screening tests.
Development and Evaluation of Screening Tests. Data
regarding the analytic and clinical validity of the screening
tests are critical in considering an NBS program. One study,
which was conducted in New York state in the 1970s, assessed
the effectiveness of a DBS screening test for ADA deficiency
based on ADA enzyme activity (107,108). This led to the
detection of 12 partially ADA-deficient patients (i.e., persons
whose erythrocytes lacked ADA but who had substantial ADA
in other cell types and who were clinically and immunologi-
cally normal) (109), but no cases of ADA SCID were detected.
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However, because of variability in the tests used, two patients
with ADA SCID were missed at one hospital. Data regarding
genotype-phenotype correlation are now accumulating for
ADA deficiency and is important to consider in NBS (110).
The majority of ADA-deficient patients have SCID, but in
15%–20% of these, the condition is diagnosed late in child-
hood or in adulthood with more variable immunodeficiency;
normal persons with partial ADA deficiency also have been
identified (111).
Identification of SCID at birth will require developing a
high-throughput screening test. Data indicate that a T-cell
count might be an effective screening tool. The phenotypic
hallmark of SCID is profound T-cell lymphopenia, with counts
substantially below the first percentile of normal; transpla-
cental maternal T-cell engraftment might cause this number
to be higher only in a limited number of cases. Compared
with healthy infants, whose total lymphocyte counts at birth
are 2,000–11,000 cells/µL (112), counts in SCID patients
are usually <1,500–2,000 cells/µL (Figure 3). CD3+ T-cell
counts in infants with SCID are typically <500 cells/µL (nor-
mal: 3,000–6,500 cells/µL) (15,16,28,113). In a study of a
large urban, primarily minority cohort of 800 healthy chil-
dren, median total lymphocyte counts at ages 0–3 months
were 5,400 cells/µL (10th –90th percentile, 3,400–7,600 cells/
FIGURE 3. Absolute lymphocyte count distributions in severe combined immunodeficiency (SCID) — 25 newborns with SCID
and 14 healthy newborns at birth evaluated at Duke University*
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Range of absolute lymphocyte counts (cells/mm3) at birth*
25 SCID newborns (age 0–16 days) 114–2,210
14 normal infants (age 0–8 days) 1,670–8,910
Range of T-cell counts (cells/mm3) at birth for*
25 SCID infants (age 0–16 days) 0–84
14 normal infants (age 0–8 days) 903–7,226
Normal number of lymphocytes (percentage of total leukocytes) at different ages†
Birth 5,500 (2,000–11,000) cells/mm3 (31%)
6 months 7,300 (4,000–13,500) cells/mm3 (61%)
21 years 2,500 (1,000–4,800) cells/mm3 (34%)
Distribution of total lymphocytes and T-cell subsets in normal healthy children at ages 0–3 months§
(N = 800) Median total lymphocyte counts 5,400 cells/µL (10th–90th percentile 3,400–7,600 cells/µL)
(N = 699) Median CD3 T-cell counts 3,680 cells/µL (10th–90th percentile 2,500–5,500 cells/µL)
(N = 699) Median CD4 T-cells counts 2,610 cells/µL (10th–90th percentile 1,600–4,000 cells/µL)
* Source: Kalman L, Lindegren ML, Kobrynski L, et al. Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2,
ARTEMIS, and ADA and severe combined immunodeficiency. Genetics in Medicine. (In press).
†Source: Altman, PL. Blood and other body fluids. Washington, DC: Federation of American Societies for Experimental Biology, 1961:125.
§ Source: Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric AIDS
clinical trials group P1009 study. J Allergy Clin Immunol 2003;112:973–80.
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µL); median CD3+ T-cell counts were 3,680 cells/µL (10th–
90th percentile, 2,500–5,500 cells/µL); and CD4+ T-cells were
2,610 cells/µL (10th–90th percentile, 1,600–4,000 cells/µL)
(114).
Development of a DBS-based high-throughput test for T-cell
lymphopenia will make possible integration of screening for
SCID into the existing NBS system. Screening tests might
detect markers on mummified T-cells (and other leukocytes)
present on DBS. Multiple types of soluble T-cell–specific
biomarkers that theoretically can be recovered from DBS have
been indicated as potential surrogates for a T-cell count. One
such biomarker is the family of cell-membrane antigens unique
to T-cells, most notably CD3, CD4, and CD8. Measurements
of these T-cell markers from DBS might be possible by using
antibody-based detection assays (115). Another potential
biomarker is the circular DNA removed when T-cell–
receptor variable genes rearrange during T-cell development.
These molecules are called T-cell antigen receptor excision
circles (TRECs) (19,116). Detection and quantitation of
TRECs from DBS should be possible by using PCR amplifi-
cation (117). TRECs, located in recently formed T cells, should
be abundant in normal newborns but absent in newborns with
SCID. Quantitation of TRECs from NBS with high-
throughput application has not been developed.
Total lymphocyte counts, as obtained in a complete blood
count, also have been proposed as a screen for lymphopenia.
However, because affected newborns often have increased
B-cell counts that cause an approximate 20% overlap with
the normal lymphocyte distributions, this approach can
potentially miss cases of SCID and require supplemental test-
ing for certain normal newborns (19). Detection of all cases
will require enumeration of total lymphocyte counts with a
manual differential and subsequent subset analysis by using
flow cytometry, neither of which can be performed on DBS
specimens. Detection of specific DNA sequences from DBS
is also possible. However, although genomic DNA-based tests
to detect the disease-causing alleles can be developed on the
basis of the detection of one or a limited number of specific
mutations, the number and wide spectrum of molecular
defects and lack of data regarding genotype-phenotype
relations that can cause SCID currently precludes develop-
ment of a specific DNA test.
Evaluation of Newborn Screening. In addition to devel-
oping a screening test, other steps need to be taken before
routine screening of newborns for SCID can be considered.
These include
• determining the analytical validity of the proposed assay;
• developing a standardized case definition of the disorder;
• developing effective follow-up protocols for screen-
positive infants;
• identifying treatment centers;
• conducting pilot testing to assess the assay’s clinical valid-
ity, clinical utility, outcomes, and costs;
• determining cost-benefit; and
• assessing ethical, legal, and social implications.
The possibility of detecting lymphopenia caused by other
genetic causes or HIV infection also needs to be considered.
Although children with these conditions do not have SCID,
any child identified with severe lymphopenia requires further
evaluation. By testing all infants, children with a fatal but treat-
able disease can be identified and treated, and valuable infor-
mation can be obtained regarding the incidence of these
disorders in the population and the frequency of different
mutations among affected persons and in the population.
In considering SCID as a possible addition to state new-
born screening, evidence-based criteria should be used but
might require re-examination in terms of weighting of differ-
ent criteria. For example, the question of whether a condition
is a key public health problem often is decided on the basis of
prevalence. Such disorders as SCID with a prevalence of per-
haps 1/100,000 might not be considered a critical public health
concern by everyone. Cost concerns (i.e., cost-effectiveness or
cost-benefit of proposed screening tests) are also important
and need to be considered systematically. Detection of a dis-
order with a low prevalence might be more cost-effective than
detection of a much more common disorder, depending on
the severity of the health outcomes, effectiveness of interven-
tions, and cost of screening and treatment (118). Economic
analysis is a way of systematically integrating and evaluating
multiple screening criteria. State newborn screening advisory
committees should consider this more objective process (119).
Workshop Recommendations for Action. Workshop
recommendations for NBS are as follows:
• Determine the feasibility of NBS for SCID.
• Establish partnerships among investigators and CDC labo-
ratory personnel to develop assays to measure T-cell
lymphocytes from DBS.
• Establish partnerships among investigators and CDC labo-
ratory personnel to validate methods to measure T-cell
lymphocytes or TRECs from DBS. Validation methods
can include blinded comparisons of T-cell counts by
using the proposed assays from DBS, with a manual
differential count from cord blood samples as the
benchmark.
• Collaborate with partners to review data regarding
population-based normal ranges of T-cells, CD4+ cells,
and TRECS at birth.
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• Pilot test a validated assay. Integrate the proposed assays
into an existing NBS panel on an investigational basis
with Institutional Review Board (IRB) approval. Dem-
onstrate adequate follow-up capacity and ability to
ensure access to treatment without financial barriers.
After pilot testing has demonstrated that NBS for T-cell
lymphopenia can be performed with an extremely high
degree of accuracy at acceptable cost and that follow-up
services and treatment can be provided to all affected chil-
dren identified through screening, a national-level body
might recommend that states include this test in the
standard NBS panel. Each state should have an advisory
committee to consider such a recommendation.
Evaluation of Screening and Diagnostic Tests
Genetic Tests and PI Diseases. Advances in molecular
biology and genetic technology have facilitated localization of
disease genes and identification of disease-causing mutations,
allowing for more rapid development of new genetic tests. PI
diseases are among the approximately 800 health conditions
for which genetic tests are available in clinical practice
(120,121). As the genetic defects associated with PI diseases
continue to be discovered, more genetic tests will become avail-
able for clinical diagnosis, carrier detection, prenatal diagno-
sis, and disease management (13,45,122).
The genetic aspects of PI diseases and their implications for
diagnosis and patient management have been extensively
reviewed (22). Mutation detection is the most reliable diag-
nostic method (45). However, because of the substantial num-
ber of mutations across the spectrum of genes that characterize
immunodeficiency, targeting one or a limited number of
mutations is inappropriate. Methodologically, DNA-based
detection involves different molecular techniques, although
DNA sequencing is the usual diagnostic method. Evaluation
of mRNA or protein also can be used because absent or low
levels of specific mRNA or protein are diagnostic for certain
PI diseases. Finally, in conjunction with a family history, clinical
and laboratory findings in certain X-linked disorders can also
provide a diagnosis.
As tools for the diagnosis and screening of PI diseases evolve,
defining and pursuing measures that will ensure their safe and
effective use become increasingly critical. Genetic testing in
the United States has developed successfully, providing
options for avoiding, preventing, and treating inherited dis-
orders. Nonetheless, application of genetic tests is increasing
in clinical and public health practice. Concerns related to rapid
commercialization of genetic tests are complex and contro-
versial. Appropriate use of tests, quality of laboratory testing,
direct-to-consumer marketing, and the potential for discrimi-
nation and stigmatization call for public health leadership.
Such leadership is needed to protect the public from inappro-
priate testing and to ensure that tests are properly evaluated
and integrated into medical and public health practice (47,56).
Evaluation of Genetic Tests. In 1999, the National Insti-
tutes of Health (NIH)-U.S. Department of Energy Task Force
on Genetic Testing published recommendations to promote safe
and effective genetic testing (47). The Task Force recognized
the need to evaluate genetic tests in population-based settings
before their use in clinical practice. To ensure the appropriate
level of review, the panel recommended that genetic tests be
evaluated according to three criteria, analytic validity, clinical
validity, and clinical utility. Systematic assessment based on these
measures provides data to determine whether a genetic test
being considered for use in population-based screening or clinical
diagnosis is safe and effective as the technology moves from
research to clinical settings (123,124). The criteria also can be
applied to screening tests and clinical algorithms.
Analytic validity is the ability of a test to measure the analyte
of interest. In the case of a genetic test, analytic validity refers
to the ability of the test to classify the genotype or analyte
related to the genotype (125). The four main elements of ana-
lytic validity are analytic sensitivity, analytic specificity, labo-
ratory quality control, and assay robustness. However, an
analytically valid test is useful only if it helps to diagnose or
predict disease (i.e., the test must also be clinically valid) (125).
Clinical validity is the accuracy with which a test predicts a
particular clinical outcome. It reflects both the sensitivity of
the test — the proportion of affected persons with a positive
test — and specificity of the test, penetrance of the mutations
identified by the test, and the prevalence of disease (123,124).
Penetrance is the proportion of persons with the mutation
who develop the disease. Clinical utility is the usefulness of
the test and the value of the information to the person being
tested. Clinical utility is assessed according to the benefits and
risks associated with the test and the ensuing result or inter-
ventions. Clinical utility focuses on health outcomes associ-
ated with testing and requires an understanding of the natural
history of the disorder.
The Foundation for Blood Research, in collaboration with
CDC, has developed a framework for assessing the availabil-
ity, quality, and usefulness of data related to genetic tests and
testing protocols (126). This approach, called ACCE
(analytic validity; clinical validity; clinical utility; and ethical,
legal, and social implications), derives from the three evalua-
tion criteria described previously, in addition to a fourth that
addresses the safeguards and impediments that should be con-
sidered in the context of the others (126,127). The evaluation
process begins only after the clinical disorder and the test set-
ting (e.g., diagnosis or population screening) have been estab-
lished. Specific questions (Table 2) help to define the disorder,
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TABLE 2. Targeted questions for evaluating genetic tests, considering analytic validity; clinical validity; clinical utility; and
ethical, legal, and social considerations
Element Component Question
Disorder/Setting
Analytic validity
Clinical validity
Clinical utility
Ethical, legal, and
social considerations
What is the specific clinical disorder to be studied?
What are the clinical findings defining the disorder?
What is the clinical setting in which the test is to be performed?
What DNA tests are associated with this disorder?
Are preliminary screening questions used?
Is it a stand-alone test or one of a series of tests?
If it is part of a series of screening tests, are all tests performed in all instances (parallel), or are only certain
tests performed on the basis of other results (series)?
Is the test qualitative or quantitative?
How often is the test positive when a mutation is present?
How often is the test negative when a mutation is not present?
Is an internal quality-control program defined and externally monitored?
Have repeated measurements been made on specimens?
What is the within- and between-laboratory precision?
If appropriate, how is confirmatory testing performed to resolve false-positive results in a timely manner?
What range of patient specimens have been tested?
How often does the test fail to give a usable result?
How similar are results obtained in multiple laboratories by using the same or different technology?
How often is the test positive when the disorder is present?
How often is the test negative when the disorder is not present?
Do methods exist to resolve false-positive results in a timely manner?
What is the prevalence of the disorder in this setting?
Has the test been adequately validated on all populations to which it might be offered?
What are the positive and negative predictive values?
What are the genotype/phenotype relations?
What are the genetic, environmental, or other modifiers?
What is the natural history of the disorder?
What is the effect of a positive (or negative) test on patient care?
If applicable, are diagnostic tests available?
Is an effective remedy, acceptable action, or other measurable benefit available?
Is that remedy or action easily accessible?
Is the test being offered to a socially vulnerable population?
What quality assurance measures are in place?
What are the results of pilot trials?
What health risks can be identified for follow-up testing or intervention?
What are the financial costs associated with testing?
What are the economic benefits associated with actions resulting from testing?
What facilities and personnel are available or easily put in place?
What educational materials have been developed and validated, and which of these are available?
Is informed consent required?
What methods exist for long-term monitoring?
What guidelines have been developed for evaluating program performance?
What is known regarding stigmatization; discrimination; privacy/confidentiality; or personal, family, and social
concerns?
Do legal problems exist regarding consent, ownership of data or samples, patents, licensing, proprietary testing,
obligation to disclose, or reporting requirements?
What safeguards have been described and are these safeguards in place and effective?
Disorder
Setting
Testing
Sensitivity
Specificity
Quality control
Robustness
Sensitivity
Specificity
Prevalence
Predictive value
Penetrance
Natural history
Intervention
Quality assurance
Pilot trials
Health risks
Economics
Facilities
Education
Monitoring
Impediments
Safeguards
Sources:
Haddow JE, Palowmaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, eds. Human genomic
epidemiology. New York, NY: Oxford University Press, 2003.
Foundation for Blood Research. FBR: Foundation for Blood Research [Website]. Scarborough, ME: Foundation for Blood Research, 2003. Available at http:/
/www.fbr.org.
the setting, and the type of testing and to address ACCE. The
first disorder to undergo an ACCE review was CF (61).
Others in progress include hereditary hemochromatosis and
breast cancer.
Development and Availability of Genetic Tests. The Task
Force has addressed the need to encourage development and
maintenance of tests for rare genetic diseases, establish a com-
prehensive system to collect data related to rare diseases, and
assess the validity of genetic tests for these conditions (47).
Evaluation of genetic tests involves collection and analysis of
data regarding analytic validity, clinical validity, clinical utility,
and other aspects from laboratories and users. However, for
selected PI diseases, genetic testing is available from only a
limited number of laboratories, or even only one laboratory,
worldwide. Immunodeficiency diseases for which clinical
genetic tests or research testing are available, based on infor-
mation from the GeneTests Laboratory Directory (121), are
provided in this report (Table 3). The directory lists 11 PI
diseases for which clinical genetic tests are offered in only one
laboratory; three diseases for which testing is available only
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TABLE 3. Genetic testing and research in primary immunodeficiency diseases listed in GeneTests* — retrieved January 27, 2003
Disorder Genes and loci Clinical genetic testing Research
Adenosine deaminase deficiency
Ataxia-telangiectasia
Autoimmune polyendocrinopathy
syndrome type 1 (APECED)
Bloom syndrome
Cartilage-hair hypoplasia
Chronic granulomatous disease
Familial atypical mycobacteriosis
Hyper Immunoglobulin D
syndrome
Lymphoproliferative disease, X-
linked
Nijmegen breakage syndrome
Properdin deficiency, X-linked
Purine nucleoside phosphorylase
deficiency
Wiskott-Aldrich syndrome
X-linked agammaglobulinemia
X-linked severe combined
immunodeficiency
Adenosine deaminase (ADA),
20q13.11
Serine-protein kinase ATM,
11q22.3
Autoimmune regulator (AIRE-1)
21q22.3
Bloom syndrome protein (BLM),
15q26
RMRP, 9p21-p12
Cytochrome B-245 light chain
(CYBA), 16q24 Cytochrome
B-245 heavy chain (CYBB),
Xp21.1 Neutrophil cytosol factor
1 (NCF1), 7q11.23 Neutrophil
cytosol factor 2 (NCF2), 1q25
Interferon-gamma receptor
alpha chain (IFNGR1), 6q23-q24
Interferon-gamma receptor beta
chain (IFNGR2), 21q22
Interleukin-12 beta chain (IL12B)
5q31-q33 Interleukin-12 receptor
beta-1 chain (IL12RB1), 19p13
Mevalonate kinase (MVK),
12q24
SH2D1A (SAP), Xq25
Nibrin (NBS), 8q21
(PFC, PFD) Xp11.4-p11.23
Purine nucleoside phosphory-
lase (PNP), 14q13
Wiskott-Aldrich syndrome
protein (WASP), Xp11
Bruton’s tyrosine kinase (BTK),
Xq21.3-q22
Interleukin-2 receptor gamma
chain (IL2RG ), Xq13.1
1 laboratory in United States
(biochemical)
1 laboratory in Italy
11 laboratories in United States;
2 laboratories in Israel (DNA-based)
1 laboratory in Switzerland
(DNA-based)
1 laboratory in United States
(biochemical and DNA-based)
1 laboratory in France (DNA-
based and biochemical)
1 laboratory in United States
(DNA-based)
1 laboratory in United States
(DNA-based)
1 laboratory in Russia
1 laboratory in the Netherlands
(DNA-based)
1 laboratory in United States
(biochemical)
1 laboratory in United States; 1
laboratory in Israel; 1 laboratory
in the Netherlands; 2 laborato-
ries in Canada (DNA-based)
1 laboratory in United States
(DNA-based)
2 laboratories in United States
(DNA-based and biochemical)
1 laboratory in United States
1 laboratory in United States
1 laboratory in Italy†
1 laboratory in United States
1 laboratory in Switzerland;† 2
laboratories in United States
1 laboratory in France†
1 laboratory in Japan; 2
laboratories in United States
3 laboratories in United States; 1
laboratory in Israel;† 1 laboratory
in Canada†
2 laboratories in United States
2 laboratories in United States
* Additional information is available at http://www.genetests.org.
† Indicates the same laboratory performing both clinical testing and research for the disorder.
outside the United States; and one disease for which testing is
available only on a research basis. The limited availability of
testing poses challenges for test development and evaluation
and presents needs and opportunities for public health research.
Data collection will require a long-term, collaborative effort
and a comprehensive, sustainable system to assess the validity
and reliability of genetic tests for PI diseases and other rare
diseases.
Guidance and criteria for transferring genetic tests from the
research and development phase to clinical and public health
practice also are needed. Certain genetic tests were developed
in research laboratories and then made available for patient
testing. For such rare diseases as PI, a laboratory that prima-
rily conducts research might be the only clinical testing site
available. A mechanism needs to be established to enable these
laboratories to participate in and contribute to the continu-
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ous test evaluation and validation process. Concurrently, cri-
teria need to be developed to guide the transition of genetic
testing from research into clinical and public health use.
For certain PI diseases, genetic tests are available only from
non-U.S. laboratories (Table 3). The Clinical Laboratory
Improvement Amendments (CLIA) require that U.S. labora-
tories refer a specimen for testing only to a CLIA-certified
laboratory or a laboratory meeting equivalent requirements as
determined by the Center for Medicare and Medicaid Ser-
vices.* To ensure access to quality genetic testing, a process is
needed to evaluate the tests and practices of non-U.S. labora-
tories that receive test referrals from the United States, deter-
mine performance equivalence to CLIA standards, and ensure
access to and availability of testing for rare disorders.
Additional needs include 1) collection of population-based
data regarding analytic validity, clinical validity, and clinical
utility for immunologic tests used to diagnose PI diseases
(Figure 2); 2) development of algorithms for use of labora-
tory tests and clinical information to increase the likelihood
of early clinical diagnosis of PI diseases; and 3) population-
based research to evaluate the utility of genetic tests as early
diagnostic tools for PI diseases, both as part of NBS programs
and for confirmatory or follow-up diagnosis.
Workshop Recommendations for Action. Recommenda-
tions from the workshop include the following:
• Evaluate potential genetic tests for their validity, utility,
and feasibility as both screening tests and confirmatory
or follow-up diagnostics in combination with other tests.
• Ensure that CLIA-compliant laboratory testing is acces-
sible, available, and valid for diagnosing rare genetic dis-
eases, including suspected PI diseases, in collaboration with
agencies providing oversight for CLIA, NIH Office of
Rare Diseases, CDC, and others.
• Support the formation of treatment networks and refer-
ral centers to ensure access to diagnosis and care for per-
sons with PI diseases.
• Collect data regarding the analytic and clinical validity of
molecular tests used for diagnosis and any proposed screen-
ing tests.
• Review gene databases in the United States and Europe
to highlight the availability and possible sources of data
regarding the validity and quality of tests.
• Identify centers for pilot testing of any proposed screen-
ing assays to determine clinical validity, in collaboration
with states, CDC, other federal agencies, and other
partners. Integrate any proposed validated assay into an
existing NBS panel on an investigational basis with IRB
approval. Demonstrate adequate follow-up capacity and
ability to ensure access to treatment without financial
barriers.
Education and Communication
To encourage early recognition of PI diseases, followed by
appropriate referral and treatment, primary-care providers,
parents, and other caregivers must be educated regarding the
symptoms of PI diseases, resources for referral, and treatment
options. The effectiveness of a health communication and
education campaign depends on the consistency of the mes-
sages and the coordination of communication strategies to
reach targeted audiences among the groups involved in PI
research and education.
Existing Efforts. Multiple agencies and organizations spon-
sor outreach and educational efforts designed to increase aware-
ness of PI diseases. NIH, Mt. Sinai Hospital, the Jeffrey Modell
Foundation (128), and IDF (129) have all targeted proactive
outreach efforts to a range of audiences (e.g., health-care pro-
viders, patients, families, and teachers), although health-care
providers have been the primary focus. Outreach activities
and resources include conferences and workshops, Internet-
based training and resources, community-based training, dis-
tribution of awareness posters, media briefings and news
releases, consulting networks, and a visiting professor program.
The National Organization for Rare Disorders (NORD) also
provides print and online resources for health-care providers
on multiple rare diseases, including PI diseases (130).
Although these educational efforts have been ongoing for
years, outcomes have not been formally evaluated. In addi-
tion, various educational activities or messages have not been
coordinated, and consensus has not been developed among
the organizations or scientists involved in educational research
related to PI diseases. Because the diseases vary in severity,
symptoms, etiology, and outcomes, coherent messages regard-
ing groups of PI diseases are difficult to create, and no agree-
ment exists concerning which disorders should be the focus
of a health communication campaign. Although educational
efforts should highlight PI diseases that can benefit from and
be targeted for early recognition and that have established cri-
teria for early clinical recognition, priorities for educational
efforts have yet to be established.
Components of Effective Programs. Effective health com-
munication and education programs should be preceded by
consensus in the scientific community regarding which PI
diseases to include in an educational program, the associated
symptoms, and the recommended screening and management
steps. To encourage early recognition, education regarding PI
diseases also will need to reach multiple audiences, including
the general public, parents, physicians, school nurses, child
care providers, and policy makers. Reaching each audience* 42 CFR§493.1242(c).
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with consistent but targeted messages will require careful
coordination among different agencies.
Attempts to reach primary-care providers, recognized as the
front line in the fight against PI diseases, must overcome
multiple barriers. Other diseases with higher prevalence com-
mand the attention of physicians. Primary-care providers with
heavy caseloads and limited time for continuing education
activities probably focus their continuing education efforts
on problems encountered most frequently among primary-
care providers. Health-care providers are most likely to attend
to the most prevalent health problems among their patients.
The prevalence of PI diseases (individually or collectively) has
not been established, although estimates classify them as rare
to extremely rare. With such high-prevalence diseases as asthma
claiming high priority for providers’ attention and concern,
focusing on less prevalent health problems might be difficult.
Development of a broad health communication campaign
for providers and the public is premature. Research to deter-
mine the prevalence and etiology of PI diseases and the effi-
cacy of early treatment must be completed before effective
messages and educational materials for the public and provid-
ers can be developed. However, pending delineation of de-
fined symptoms, disease groups, and treatment
recommendations, health communication efforts still can be
useful. Although research has not yet yielded a defined set of
educational goals related to PI diseases, health communica-
tion efforts can be used in the interim to increase awareness
among scientists and clinicians. Certain health-care providers
might be unaware of PI diseases and research, and researchers
might be unaware of opportunities for funding and participa-
tion in PI investigations.
Workshop Recommendations for Action. Workshop rec-
ommendations include the following:
• Target health-care providers and scientists for early-stage
communication activities. Increase their awareness of stud-
ies under way, questions motivating research programs,
opportunities for participation and funding, and resources.
• Use research concerning the outcomes of previous and
ongoing educational programs to determine how best to
reach target audiences with information related to PI dis-
eases. Systematically analyze the range of outreach efforts
to determine 1) information reach, 2) frequency of mes-
sage contact, and 3) interaction of messages from differ-
ent organizations. Use evidence-based outcome
assessments to determine awareness, knowledge, and uses
of information from previous education and communi-
cation programs.
• Convene a working group of health communication spe-
cialists to establish campaign goals, audiences, and strate-
gies, even as research continues and consensus is reached
regarding disorders to include in a health communica-
tion campaign and case definitions and clinical recom-
mendations are developed. The working group should
— determine additional formative research needed to
assess target audiences’ awareness, knowledge, and
behaviors related to PI;
— develop or revise materials that are consistent with
campaign goals;
— develop additional materials as needed to achieve
campaign goals;
— pretest materials with target audiences;
— disseminate messages that are consistent with recom-
mendations from pretesting, and
— include process and evidence-based outcome evalua-
tions as part of campaign planning.
Conclusion
This report presents a framework for stakeholders and policy
makers who will collaborate to define the future of an emerg-
ing and promising field of study that can markedly improve
health in persons with PI diseases. The recommended inter-
ventions encompass multiple goals — helping children, edu-
cating clinicians, developing and maintaining awareness of PI
diseases, and providing information for policy development
and change. Additional efforts are needed to define priorities
in future public health actions and associated costs and ben-
efits. The proposed public health framework is critical for PI
diseases and serves as a model for other genetic disorders that
can benefit from early diagnosis and opportunities for inter-
ventions to improve health outcomes.
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Terms and Abbreviations Used in This Report*
ACCE analytic validity; clinical validity; clinical utility; and ethical, legal, and social implications
ADA adenosine deaminase gene
AICDA activation-induced cytidine deaminase gene
allele alternative form of a gene that exists at a specific gene location (locus) on a chromosome
analyte substance measured by a laboratory test
APECED autoimmune polyendocrinopathy with candidiasis and ectodermal dysplasia
autosome nuclear chromosomes other than sex chromosomes; the diploid human genome consists of
46 chromosomes: 22 pairs of autosomes, and one pair of sex chromosomes (the X and Y
chromosomes)
autosomal dominant abnormal gene on one of the autosomal chromosomes from either parent, transmission of which
can cause a particular trait or disorder
autosomal recessive abnormal gene on one of the autosomal chromosomes from each parent, transmission of both
abnormal genes is required to cause a particular trait or disorder
B cell antibody-producing lymphocyte; a type of white blood cell
birth defect defect present at birth, whether caused by mutant genes or by prenatal events that are not genetic
BTK Bruton’s tyrosine kinase gene
CF cystic fibrosis
CFF Cystic Fibrosis Foundation
CGD chronic granulomatous disease
chromosome one of the thread-like structures in the cell nucleus; consists of chromatin and carries genetic
information (DNA); human cells normally contain 46 chromosomes (23 pairs)
CLIA Clinical Laboratory Improvement Amendments
* Additional definitions are available at http://www.genome.gov/glossary.cfm.
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codon three-base sequence of DNA or RNA that specifies an amino acid
complement a set of serum proteins that binds antigen-antibody complexes to kill microorganisms
CVID common variable immunodeficiency
DBS dried blood spot
deletion particular kind of mutation; loss of a piece of DNA from a chromosome
DNA deoxyribonucleic acid
EDA-ID ectodermal dysplasia associated with immune deficiency
enzyme protein that facilitates a specific biochemical reaction
ESID European Society for Immunodeficiencies
exon protein-coding DNA sequence of a gene
gene functional and physical unit of heredity, consisting of a segment of DNA arranged linearly along a
chromosome; the majority of genes contain the information for making a specific protein leading
to a particular characteristic or function
gene product biochemical material, either RNA or protein, resulting from expression of a gene
gene therapy treatment of a genetic disorder by replacing, supplementing, or manipulating nonfunctional genes
with normal genes
genetic marker landmark for a target gene, either a detectable trait that is inherited with the gene or a distinctive
segment of DNA
genetic testing examining a sample of blood or other body fluid or tissue for biochemical, chromosomal, or ge-
netic markers that indicate the presence or absence of genetic disease
genome complete DNA sequence, containing all genetic information and supporting proteins, in the chro-
mosomes of a person or species
genomics study of the functions and interactions of all the genes in the genome, including their interactions
with environmental factors
genotype a person’s genetic makeup, specifically the alleles present at specific gene loci
genotype/phenotype association between the presence of a certain mutation or mutations (genotype) and the resulting
correlation physical trait, abnormality, or pattern of abnormalities (phenotype)
HIV human immunodeficiency virus
HTCs hemophilia treatment centers
Human Genome Project international research project to map each human gene and to completely sequence human DNA
IDF Immune Deficiency Foundation
Ig immunoglobulin
ILR2G interleukin 2 receptor gamma gene
incidence number or proportion of new cases of a specified condition among a population during a specified
period
inherited transmitted through genes from parents to offspring
insertion type of mutation in which a DNA sequence is inserted into a gene, disrupting the normal structure
and function of that gene
IRB Institutional Review Board
IVIG intravenous immunoglobulin
JAK3 Janus-associated kinase 3 gene
LAD leukocyte adhesion defect
locus position on a chromosome where a specific gene is located
microarray technology methods for measuring expression of multiple genes simultaneously under specific conditions rela-
tive to baseline (i.e., up regulation or down regulation)
missense a genetic mutation that alters the amino acids in the protein product of a gene
mRNA messenger RNA
mutation permanent heritable change in the molecular sequence of a gene
NADPH nicotinamide-adenine dinucleotide phosphate
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NBS newborn screening
Negative predictive value likelihood that a person with a negative test result is actually not affected by the disease
NHGRI National Human Genome Research Institute
NIH National Institutes of Health
nonsense a genetic mutation in single base-pair substitution in DNA resulting in premature stop codons in
the genetic code
NORD National Organization for Rare Disorders
NSQAP Newborn Screening Quality Assurance Program
PCR polymerase chain reaction
penetrance frequency with which a genotype manifests itself in a specific phenotype
phenotype clinical presentation or expression of a specific gene or genes, environmental factors, or both
PI primary immunodeficiency
PKU phenylketonuria
positive predictive value likelihood that a person with a positive test result is actually affected by the disease
prevalence number or proportion of existing cases of a specified condition in a population
RAG recombination-activating gene
regulatory (gene) a genetic mutation that affects aspects of gene expression
RNA ribonucleic acid
SCID severe combined immunodeficiency
screening testing on a population basis to identify persons at risk for developing specific disorders
sensitivity frequency with which a test yields a positive result when the abnormality or disease in question is
actually present in the person being tested
sequencing process by which the nucleotide sequence is determined for a segment of DNA
sex chromosome the X and Y chromosomes
single-gene disorder a disorder caused by one or a pair of mutant alleles at a single locus
specificity frequency with which a test yields a negative result when the abnormality or disease in question is
not present in the person being tested
splice site a genetic mutation that can lead to frameshift mutations
T cell a white blood cell or lymphocyte that develops in the thymus and mediates cellular immune responses
TRECs T-cell antigen receptor excision circles
UDC universal data collection
WAS Wiskott-Aldrich syndrome
X-linked recessive genes transmitted on the X chromosome
XLA X-linked agammaglobulinemia
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1. Primary immunodeficiency diseases are usually . . .
A. single-gene disorders of the immune system.
B. fatal without early treatment.
C. disorders characterized by recurrent bacterial/viral infections.
D. all of the above.
2. Common variable immunodeficiency (CVID) is characterized by all
of the following features, except . . .
A. low levels of immunoglobulin G, M, or A.
B. recurrent infection of the respiratory or gastrointestinal tract.
C. an increased incidence of lung cancer.
D. death from chronic lung disease.
3. Population-based surveillance for PI diseases should involve . . .
A. active assessment of inpatient hospitalization records, outpatient clinic
records, and vital records in a defined geographic area.
B. evaluation of population-based mortality data from death certificates.
C. computerized inpatient databases from hospital discharge or managed
care organizations.
D. prevalence estimates based on case-based disease registries.
E. all of the above.
F. A, B, and C.
4. The goal of early clinical recognition is to . . .
A. reduce disability and premature mortality from PI disease.
B. identify newborns with PI disease.
C. identify those persons with symptoms of PI diseases for referral to an
immunologist.
D. A and C.
E. all of the above.
5. Which of the following is not true regarding newborn screening?
A. Newborn screening programs were first begun to identify infants with
phenylketonuria.
B. Severe combined immunodeficiency (SCID) is a candidate for
newborn screening because it is fatal during infancy without treatment
and because intervention before appearance of clinical symptoms can
improve outcomes.
C. Newborn screening for SCID can be performed by screening for B-cell
lymphopenia.
D. Detecting specific DNA sequences for disease-causing alleles for SCID
is possible by using dried blood spots.
6. The clinical validity of a genetic test is . . .
A. the ability of a test to measure the gene of interest.
B. dependent on the penetrance of the genetic mutation.
C. focuses on the health outcomes associated with testing.
D. reflective of the proportion of affected persons with a positive test.
E. B and D.
Goal and Objectives
This MMWR provides recommendations regarding public health strategies for primary immunodeficiency (PI) diseases. These recommendations were prepared by
CDC staff and other specialists in PI diseases after consultation with a multidisciplinary panel. The goal of this report is to familiarize readers with a public health
framework for addressing health problems resulting from a group of primarily single-gene disorders. Upon completion of this continuing education activity, the reader
should be able to describe 1) the four components of a public health framework; 2) how public health assessment can be applied to PI and other genetic diseases; 3) the
framework for evaluating genetic tests, including analytic validity, clinical validity, clinical utility, and ethical, legal, and social considerations; 4) two public health
interventions to increase early diagnosis and treatment for genetic diseases (i.e., newborn screening and early clinical recognition); and 5) the key components of an
effective health education program for PI diseases.
To receive continuing education credit, please answer all of the following questions.
7. Educational efforts for PI diseases need to . . .
A. tailor messages to targeted groups of health-care providers.
B. use outcome assessments to determine knowledge and uses of
education messages.
C. provide consistent messages regarding symptoms, screening, and
management.
D. include different strategies for disseminating information.
E. be evidence-based.
F. all of the above.
8. Diagnostic testing for T-cell disorders involves all of the following,
except . . .
A. complete blood count (CBC) with differential.
B. lymphocyte phenotyping.
C. mitogen stimulation.
D. nitroblue tetrazolium (NBT).
9. Which of the following statements is true?
A. Defects in Bruton’s tyrosine kinase (BTK) gene results in defects of
B-cell function.
B. SCID caused by defects in the adenosine deaminase (ADA) gene is
inherited as an X-linked disorder.
C. Lack of CD18 results in a disorder known as Chédiak-Higashi.
D. Patients with Wiskott-Aldrich syndrome have defective platelets
caused by antiplatelet antibodies.
10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
11. Which best describes your professional activities?
A. Physician.
B. Nurse.
C. Health educator.
D. Office staff.
E. Other.
12. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
Vol. 53 / No. RR-1 Recommendations and Reports CE-3
Detach or photocopy.
M
M
W
R
 R
e
sp
o
n
se
 F
o
rm
 f
o
r 
C
o
n
ti
n
u
in
g
 E
d
u
ca
ti
o
n
 C
re
d
it
Ja
n
u
a
ry
 1
6
, 
2
0
0
4
/V
o
l.
 5
3
/N
o
. 
R
R
-1
A
p
p
ly
in
g
 P
u
b
lic
 H
ea
lt
h
 S
tr
a
te
g
ie
s 
to
 P
ri
m
a
ry
Im
m
u
n
o
d
ef
ic
ie
n
cy
 D
is
ea
se
s
A
 P
o
te
n
ti
a
l A
p
p
ro
a
ch
 t
o
 G
en
et
ic
 D
is
o
rd
er
s
To
 re
ce
iv
e 
co
nt
in
ui
ng
 e
du
ca
tio
n 
cr
ed
it,
 y
ou
 m
us
t
1.
pr
ov
id
e 
yo
ur
 c
on
ta
ct
 in
fo
rm
at
io
n;
2.
in
di
ca
te
 y
ou
r c
ho
ic
e 
of
 C
M
E,
 C
EU
, o
r C
NE
 c
re
di
t;
3.
an
sw
er
 a
ll 
o
f t
he
 te
st
 q
ue
st
io
ns
;
4.
si
gn
 a
nd
 d
at
e 
th
is
 fo
rm
 o
r a
 p
ho
to
co
py
;
5.
su
bm
it 
yo
ur
 a
ns
w
er
 fo
rm
 b
y 
Ja
nu
ar
y 
16
, 2
00
7.
Fa
ilu
re
 to
 c
om
pl
et
e 
th
es
e 
ite
m
s 
ca
n 
re
su
lt 
in
 a
 d
el
ay
 o
r
re
jec
tio
n o
f y
ou
r a
pp
lic
ati
on
 fo
r c
on
tin
uin
g e
du
ca
tio
n c
red
it.
La
st
 N
am
e
Fi
rs
t N
am
e
St
re
et
 A
dd
re
ss
 o
r P
.O
. B
ox
Ap
ar
tm
en
t 
or
 
Su
ite
Ci
ty
St
at
e
ZI
P 
Co
de
Ph
on
e 
Nu
m
be
r
Fa
x 
Nu
m
be
r
E-
M
ai
l A
dd
re
ss
Si
gn
at
ur
e
D
at
e 
I C
om
pl
et
ed
 E
xa
m
Fi
ll 
in
 th
e 
ap
pr
op
ria
te
 b
lo
ck
s 
to
 in
di
ca
te
 y
ou
r a
ns
we
rs
. R
em
em
be
r, 
yo
u 
m
us
t a
ns
we
r a
ll
of
 th
e 
qu
es
tio
ns
 to
 re
ce
ive
 c
on
tin
ui
ng
 e
du
ca
tio
n 
cr
ed
it!
1.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
14
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
2.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
15
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
3.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
[  ]
 F
16
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
4.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
17
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
5.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
18
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
6.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
19
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
7.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
[  ]
 F
20
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
8.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
21
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
9.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
22
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
10
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
[  ]
 F
23
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
11
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
24
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
12
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
25
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
13
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
[  ]
 F
26
.
[  ]
 A
[  ]
 B
[  ]
 C
[  ]
 D
[  ]
 E
[  ]
 F
Ch
ec
k 
On
e
CM
E 
Cr
ed
it
CN
E 
Cr
ed
it
CE
U 
Cr
ed
it
(Continued on pg CE-4)
13. Each month, approximately how many patients do you treat?
A. None.
B. 1–5.
C. 6–20.
D. 21–50.
E. 51–100.
F. >100.
14. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 hours but <4.0.
D. >4.0 hours.
15. After reading this report, I am confident I can describe the four
components of a public health framework.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe how public
health assessment can be applied to PI and other genetic diseases.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe the framework
for evaluating genetic tests, including analytic validity, clinical
validity, clinical utility, and ethical, legal, and social considerations.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can describe two public
health interventions to increase early diagnosis and treatment for
genetic diseases (i.e., newborn screening and early clinical
recognition).
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. After reading this report, I am confident I can describe the key
components of an effective health education program for PI diseases.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–9.
1. D; 2. C; 3. F; 4. D; 5. C; 6. E; 7. F; 8. D; 9. A.
20. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. The teaching strategies used in this report (text, figures, and tables)
were useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. Overall, the presentation of the report enhanced my ability to
understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. The content of this activity was appropriate for my educational needs.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR subscription.
F. Other.
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